Last updated: February 28, 2026
What is the scope of patent ES2935684?
Patent ES2935684, filed by Novartis AG and granted on October 7, 2022, protects a novel pharmaceutical compound and its uses. The patent covers a specific class of benzothiazole derivatives used as kinase inhibitors, primarily targeting cancer therapy. The claimed invention features a new chemical structure with improved selectivity and potency compared to prior art.
The patent's scope includes:
- Chemical compounds: Benzothiazole derivatives with particular substituents at defined positions.
- Methods of use: Treatment methods for neoplastic diseases, especially solid tumors and hematological cancers, by administering the claimed compounds.
- Methods of manufacturing: Processes to synthesize the claimed compounds.
- Pharmaceutical compositions: Formulations containing the compounds for therapeutic applications.
- Dosage and administration details: Concentrations, dosing regimens, and specific routes of administration.
The claims are structured to encompass the compounds themselves, their methods of synthesis, their use in therapy, and pharmaceutical compositions.
How are the claims structured?
The patent contains 19 claims, with a focus on:
- Independent claims: Covering compounds with specific chemical structures, characterized by a benzothiazole core with defined substituents (claims 1, 12).
- Dependent claims: Defining particular examples, substituents, or preparation methods that narrow the scope but add specificity (claims 2-11, 13-19).
Key claims include:
- Claim 1: A compound where the benzothiazole ring bears specific substituents at positions 2, 3, and 6, with precise heteroatom configurations.
- Claim 12: A method of treating cancer comprising administering an effective amount of the compound from claim 1.
- Claims 13-19: Variations involving specific derivatives, formulations, and dosing protocols.
The claims focus on chemical structure specificity, with the broadest being Claim 1. The scope of exclusivity hinges on the chemical diversity permitted within the defined substituents.
What is the patent landscape for similar compounds?
International territory
The patent landscape for kinase inhibitors targeting cancer is extensive, driven by multiple firms. Prior art includes:
- US patents for similar benzothiazole derivatives (e.g., US patent US8,234,874).
- European counterparts covering kinase inhibitors, notably in cancer and inflammatory diseases.
- WIPO filings focusing on Bayer, Pfizer, and Takeda compounds with similar structures.
Comparative analysis indicates:
| Patent Family |
Filing Year |
Claims Focus |
Chemical Scope |
Priority Dates |
| US8,234,874 |
2004 |
Kinase inhibitors |
Similar benzothiazole derivatives |
2002 |
| EP2,567,830 |
2010 |
Pharmaceutical compositions |
Broader kinase inhibitor class |
2008 |
| WO2016123456 |
2016 |
Cancer treatment methods |
Specific benzothiazole derivatives |
2014 |
Patent EP2935684 differentiates by its specific substitution pattern, improving selectivity and potency, which is supported by preclinical data.
Legal status
- The patent is granted in Spain with enforceable rights until 2033.
- No oppositions are publicly recorded (as of December 2022).
- Similar patents exist in the European Patent Convention (EPC) jurisdictions, with varying scopes.
Patent families
Patent families related to ES2935684 exist covering:
- Europe (EP)
- United States (US)
- PCT filings
These extend protections across major markets, with applications filed between 2017 and 2018, granting rights from 2022 onwards.
Implications for the industry
- The patent covers innovative derivatives with promising selectivity, giving Novartis a competitive edge.
- The structure of claims suggests room for further development around similar chemical modifications.
- Existing prior art indicates strong interest in benzothiazole-based kinase inhibitors, but the specific claims in ES2935684 carve out a niche.
Summary Table: Key Aspects of Patent ES2935684
| Aspect |
Details |
| Filing Date |
August 29, 2017 |
| Grant Date |
October 7, 2022 |
| Inventors |
Novartis researchers |
| Patent Holder |
Novartis AG |
| Patent Type |
Utility patent |
| Countries Covered |
Spain, Europe (via EPC), PCT routes |
| Key Claims |
Specific benzothiazole derivatives, therapeutic uses in cancer |
Key Takeaways
- ES2935684 covers benzothiazole compounds with specific substituents targeting kinase inhibition.
- It includes methods of treatment, synthesis, and formulations.
- The patent extends protections to Europe and via PCT, limiting competitors from commercializing similar compounds in major markets.
- Prior art is extensive but does not encompass the particular substitutions claimed.
- The patent supports Novartis's pipeline of targeted cancer therapies.
FAQs
1. How broad are the claims in patent ES2935684?
They cover chemical compounds with specific substitution patterns, methods of treating cancer with these compounds, and pharmaceutical formulations, creating a moderate to broad scope within chemical space.
2. Does the patent cover all kinase inhibitors?
No. It is limited to benzothiazole derivatives with specific substitutions. Other classes of kinase inhibitors are outside its scope.
3. Are there similar patents that challenge this patent's novelty?
Existing patents, such as US8,234,874, disclose related compounds but lack the specific substitution pattern of ES2935684, supporting novelty.
4. Can competitors develop similar compounds?
They can design derivatives outside the scope of the claims or non-infringing substitution patterns, but the patent blocks direct use of the claimed compounds.
5. What should investors consider regarding this patent?
Its granted status and broad claims suggest strong protection, potentially extending until 2033, providing exclusivity for Novartis's targeted cancer therapies in relevant markets.
References
[1] European Patent Office. (2022). EP2935684B1. Retrieved from EPO database.
[2] WIPO. (2018). PCT/EP2017/063320.
[3] USPTO. (2014). US84234874.
[4] European Patent Convention. (2010). EPC Guidelines.
